(NASDAQ: PBYI) Puma Biotechnology's forecast annual revenue growth rate of 0.69% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 152.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.7%.
Puma Biotechnology's revenue in 2025 is $230,468,000.On average, 2 Wall Street analysts forecast PBYI's revenue for 2025 to be $10,735,776,904, with the lowest PBYI revenue forecast at $10,735,776,904, and the highest PBYI revenue forecast at $10,735,776,904. On average, 2 Wall Street analysts forecast PBYI's revenue for 2026 to be $11,709,884,942, with the lowest PBYI revenue forecast at $11,688,304,244, and the highest PBYI revenue forecast at $11,731,465,640.
In 2027, PBYI is forecast to generate $12,332,500,469 in revenue, with the lowest revenue forecast at $12,331,756,307 and the highest revenue forecast at $12,333,244,631.